Evopoint Biosciences, an innovation-driven biopharmaceutical company in SIP, was listed on the STAR Market of the Shanghai Stock Exchange on Sept 16, becoming the 75th listed company—the 24th STAR Market-listed company—in SIP.

Founded in SIP in 2017, Evopoint Biosciences aims to translate cutting-edge science into transformative therapies to fulfil unmet medical needs worldwide. The company has made deep strategic deployments in critical illness areas such as precision oncotherapy and multidrug-resistant bacterial infection therapies. Several products have entered Phase III clinical trials or NDA (New Drug Application) stage, and have received express registration qualifications or breakthrough therapy designations at home and abroad.

The company has secured licensing agreements with multiple domestic and international companies, with the total transaction value exceeding US$2 billion. This listing marks the beginning of a new journey for it to accelerate global expansion and craft a full-chain system covering innovative drug R&D, production, and marketing.

September 16, 2026